Accessibility StatementSkip Navigation SECAUCUS, N.J., Nov. 3, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during Citi's 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025, at 3:15 p.m. Eastern Time. The fireside chat and Q&A session will be webcast ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company, today announced a significant strengthening of its balance sheet and liquidity position to support its 2026 AI infrastructure development and is also ple ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025 MIAMI, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), a U.S. developer of Tier III-grade high-performance computing (HPC) infrastructure, plans to announce its financial results for the quarter ended September 30, 2025(all amounts in U.S. dollars, unles ...

Accessibility StatementSkip Navigation The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation SECAUCUS. N.J., Oct. 27, 2025 /PRNewswire/ -- Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology® Clinical Practice, a publication of the American Academy of Neurology. Conducte ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, int ...

Quest Diagnostics (NASDAQ:DGX) posted better-than-expected earnings for the third quarter on Tuesday.While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP earnings per share guidance to a range of $8.58 to $8.66 from a prior range of $8.60 to $8.80, which may be weighing on shares.The company brought in $2.82 billion in revenue, which was up 13.1% from last year and ahead of estimates of $2.74 billion. Quest also reported adjusted earnings ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025MIAMI, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), a U.S. developer of Tier III-grade high-performance computing (HPC) infrastructure, today announced the appointment of Ajay Gupta, CPWA, CRPC, CIMA, to its board of directors (the “Board”), effective ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Key Takeaways Quest Diagnostics' Q3 EPS of $2.60 beat estimates and rose 13% year over year.DGX's revenues grew 15.2% to $2.82B due to a 12.5% rise in test volumes and higher revenue per requisition.DGX's gross margin expanded 110 bps to 33.7%, and full-year revenue and EPS guidance were raised.Quest Diagnostics Inc.’s (DGX) third-quarter 2025 adjusted earnings per share (EPS) of $2.60 beat the Zacks Consensus Estimate by 3.59%. The metric also exceeded the year-ago adjusted figure by 13%.Certain one-time e ...

Quest Diagnostics (NYSE:DGX) Q3 2025 Earnings Call October 21, 2025 08:30 AM ET Company ParticipantsJim Davis - CEOShawn Bevec - VP of Investor RelationsSam Samad - CFOConference Call ParticipantsPito Chickering - AnalystAndrew Brackman - Equity Research AnalystPatrick Donnelly - AnalystKevin Caliendo - AnalystErin Wright - AnalystLuke Sergott - AnalystMichael Cherny - Equity Research AnalystElizabeth Anderson - Healthcare Equity Research AnalystMichael Ryskin - AnalystJack Meehan - AnalystTycho Peterson - ...